Kiniksa Pharmaceuticals报告2024年初步产品净收入为4.164亿美元

2025-01-13 20:52

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) on Monday reported preliminary ARCALYST net product revenue of $121.9 million for the fourth quarter, compared to consensus revenue estimates of 123.20 million.
The company expects full year 2024 revenue of $416.4 million, compared to consensus revenue estimates of 423.87 million.
Kiniksa expects 2025 ARCALYST net product revenue of between $560 million and $580 million.
As of December 31, 2024, Kiniksa had $243.6 million of cash, cash equivalents, and short-term investments.
As of the end of the fourth quarter of 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment.
KNSA -1.15% premarket to $19.7.
Source: Press Release

More on Kiniksa Pharmaceutical